Latest Hotspot

Lirum BioMed's LX-101 Shows Promise Against IGF-Linked Tumors,Set for 2024 ESMO Spotlight

20 March 2024
3 min read

Lirum Therapeutics, Inc., a pioneering enterprise operating in the clinical-phase biopharmaceutical industry, is dedicated to developing treatments for severe illnesses. The company has recently reported that its compelling findings regarding LX-101, an innovative therapy in clinical trials that is designed to specifically target the IGF-1R, will be showcased at the upcoming 2024 ESMO Congress for Sarcoma and Rare Cancers. This significant event is scheduled to unfold in Lugano, Switzerland, between the dates of March 14th and 16th.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Lirum's research encompasses clinically substantiated reports of LX-101 demonstrating significant preclinical efficacy in combating tumors that are known to involve the IGF-1R signaling pathway. This includes cancer types that exhibit genetic changes impacting the IGF-1R pathway directly or have an elevated expression of IGF-1R.

In light of these encouraging findings and the supporting clinical evidence, Lirum is currently strategizing future clinical studies to assess LX-101 in treating various cancer forms, in both children and adults, that are notably connected with aberrations in the IGF-1/IGF-1R axis. Additionally, Lirum is exploring the potential of LX-101 as a treatment for specific autoimmune conditions, such as thyroid dye disease, where the role of IGF-1R has been both clinically and commercially acknowledged.

Regarding peptide-based therapeutics, these compounds integrate peptides with other chemical entities to amplify their medicinal impact. In the case of LX-101, its molecular design specifically targets the convergence of FOLR1 and IGF-1. FOLR1 is a targeted receptor found in excess on certain tumor cells, making it an attractive molecular target for precision therapies. Conversely, IGF-1 is an influential factor in cellular development and multiplication.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

中度可信度描述已自动生成

According to the data provided by the Synapse Database, As of March 18, 2024, there are 1 investigational drugs for the FOLR1 and IGF-1 target, including 4 indications, 1 R&D institutions involved, with related clinical trials reaching 4, and as many as 585 patents.

LX-101 shows promise as a potential treatment for Graves Ophthalmopathy and potentially other diseases within its therapeutic areas. As it progresses through the IND application phase, further clinical trials will be conducted to evaluate its safety and efficacy.

图形用户界面, 文本, 网站

描述已自动生成

Making the Most Out of Synapse: Searching for Levetiracetam
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Levetiracetam
20 March 2024
Levetiracetam, a diminutive molecular entity, has been engineered to hone in on the synaptic vesicle protein 2A (SV2A) as a modulation target.
Read →
Promising Results for Nuvectis Pharma's NXP800 in ARID1a-Altered Ovarian Cancer
Latest Hotspot
3 min read
Promising Results for Nuvectis Pharma's NXP800 in ARID1a-Altered Ovarian Cancer
20 March 2024
Nuvectis Pharma Releases Promising Initial Results from Early-Stage NXP800 Study in Platinum-Resilient Ovarian Cancer with ARID1a Alterations.
Read →
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
Hot Spotlight
7 min read
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
19 March 2024
On March 11th, Boehringer Ingelheim partnered with Sosei Group in an exclusive deal to create and market a novel schizophrenia drug, a GPR52 agonist.
Read →
Who should not take semaglutide?
Knowledge Base
2 min read
Who should not take semaglutide?
19 March 2024
Individuals who should not take semaglutide are:Those with multiple endocrine neoplasia type 2 (MEN2),medullary thyroid cancer,diabetic ketoacidosis (DKA)
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.